Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;55(1):2200258.
doi: 10.1080/07853890.2023.2200258.

In silico and in vivo demonstration of the regulatory mechanism of Qi-Ge decoction in treating NAFLD

Affiliations

In silico and in vivo demonstration of the regulatory mechanism of Qi-Ge decoction in treating NAFLD

Chong Peng et al. Ann Med. 2023 Dec.

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD), a chronic and progressive liver disease, often causes steatosis and steatohepatitis. Qi-Ge decoction (QGD) shows a good effect against NAFLD in the clinic. But the molecular mechanism for QGD in improving NAFLD is unknown.

Purpose: This study explored the molecular mechanism of QGD in NAFLD model rats using comprehensive network pharmacology, molecular docking and in vivo verification strategies.

Methods: Active components and targets of QGD were obtained from public database. The overlapped genes between QGD and NAFLD targets were analyzed by enrichment analysis. Active components and targets were used to predict molecular docking analysis. Finally, seven key targets were screened out and the gene expression were verified in the NAFLD rat's liver tissues after QGD treatment.

Results: Fifty-eight common QGD therapeutic targets were associated with NAFLD. Molecular docking demonstrated that seven targets had strong binding ability for the corresponding active ingredients. GO analysis identified 18 biological process entries, which were mainly related to regulation of lipid storage, lipid localization and peptide transport. KEGG analysis identified multiple signaling pathways, which were mainly associated with tumor necrosis factor signaling and NAFLD. In vivo data confirmed that the effect of QGD in the treatment of NAFLD was mainly exerted through improving liver steatosis and inflammatory cell infiltration. Additionally, QGD upregulated the expression of MAPK8 and ESR1 and downregulated the transcriptional expression of IL6, VEGFA, CASP3, EGFR and MYC. These targets may affect lipid metabolism by regulating lipid storage and inflammation.

Conclusion: The integration of results obtained in silico and in vivo indicated that QGD regulates multiple targets, biological processes and signaling pathways in NAFLD, which may represent a complex molecular mechanism by which QGD improves NAFLD.Key messagesQGD intervention is related to multiple biological processes such as inflammation, oxidation and cell apoptosis in NAFLD.Lipid and atherosclerosis, TNF signaling pathway, IL-17 signaling pathway, non-alcoholic fatty liver disease and AGE-RAGE signaling pathway in diabetic complications are the main pathways for QGD intervention NAFLD.The active components of QGD can form good binding with relevant target proteins through intermolecular forces, exhibiting excellent docking activity.

Keywords: NAFLD; Qi-ge decoction; in silico study; in vivo validation; molecular docking; network pharmacology.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
HPLC of Qi-ge decoction.
Figure 2.
Figure 2.
The workflow of study on the mechanism of Qi-ge decoction in the treatment of NAFLD.
Figure 3.
Figure 3.
The Venn diagram of the potential targets sharing by Qi-Ge decoction (QGD) in the treatment of NAFLD (A) and QGD-compound-target-NAFLD network (B).①: 1,7-Dihydroxy-3,9-dimethoxy pterocarpene. ②: (6aR,11aR)-9,10-dimethoxy-6a,11a-dihydro-6H-benzofurano[3,2-c]chromen-3-ol.
Figure 4.
Figure 4.
PPI network of potential targets (A) and core targets with higher than average degrees (15.7) (B).
Figure 5.
Figure 5.
GO enrichment analysis (A), KEGG enrichment analysis (B) and pathway-target network (C).
Figure 6.
Figure 6.
Molecular docking diagram of the active compounds of QGD and key targets.
Figure 7.
Figure 7.
2D molecular docking diagram of the active compounds of QGD and key targets.
Figure 8.
Figure 8.
Effects of the Qi-Ge decoction (QGD) on (A) weight, (B) liver index, serum (C) total cholesterol (TC), (D) triglyceride (TG), (E) low-density lipoprotein cholesterol DL-C), (F) high-density lipoprotein cholesterol (HDL-C) activities and (G) the macroscopic appearance of liver in rats with NAFLD. Data are expressed as means ± SD (n = 10). ∗p < .05 compared with the model group.
Figure 9.
Figure 9.
Effects of the Qi-Ge decoction (QGD) on histopathological changes in rats with NAFLD (hematoxylin and eosin staining; 400×).
Figure 10.
Figure 10.
Validation of the core genes using real-time PCR. β-actin was used for normalization in real-time PCR (A–G). Data are expressed as means ± SD (n = 3). ∗p < .05 compared with the model group.

Similar articles

Cited by

References

    1. Oates JR, McKell MC, Moreno-Fernandez ME, et al. . Macrophage function in the pathogenesis of non-alcoholic fatty liver disease: the mac attack. Front Immunol. 2019;10:1. - PMC - PubMed
    1. Loomba R, Seguritan V, Li W, et al. . Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2017;25(5):1054.e1055–20. - PMC - PubMed
    1. Ma Z, Xu C, Kang X, et al. . Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study. J Transl Med. 2020;18(1):133. - PMC - PubMed
    1. Dai X, F J, Chen Y, et al. . Traditional Chinese medicine in nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Chin Med. 2021;16(1):68. - PMC - PubMed
    1. Hung TC, Zhao N, Huang C, et al. . Exploring the mechanism of PingTang no.5 capsule on nonalcoholic fatty liver disease through network pharmacology and experimental validation. Biomed Pharmacother. 2021;138:111408. - PubMed

Publication types